Cochrane: anti‑amyloid drugs ineffective raise swelling
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Cochrane review of 17 trials with 20,342 participants found no clinically meaningful benefit from anti‑amyloid drugs.
- Francesco Nonino said the evidence shows no meaningful difference for patients, despite earlier statistically significant results.
- IRCCS Institute of Neurological Sciences of Bologna, Italy led the analysis, highlighting increased risk of brain swelling and bleeding in treated patients.
Why it matters: Patients and insurers lose billions on ineffective treatments, while pharma faces a setback; the 20,342‑person review forces a pivot to new targets, reshaping R&D budgets and delaying market launches.
